Microdosing
Microdosing, taking tiny, sub-perceptual doses of a psychedelic a few times a week for focus, mood or creativity, is one of the most popular things people do with these drugs, and one of the clearest cases where rigorous evidence undercuts a popular practice. The anecdotes are glowing, the surveys are positive, and the open-label studies look promising. But when researchers run proper double-blind, placebo-controlled trials, the benefits very largely disappear: people on placebo improve just as much, and the small differences that remain track whether participants guessed they had the real drug. This page tells that story honestly. It also notes the two things the null trials do not settle: whether some narrow effect survives in the right population, and whether taking a serotonergic drug repeatedly for months or years is safe, which, remarkably, almost nobody has properly studied.
What does the research on microdosing show? Microdosing means taking very small, sub-perceptual doses of a psychedelic such as psilocybin or LSD, usually on a repeated schedule, in the hope of subtle benefits to mood, focus or creativity without a full psychedelic experience. It is popular outside the clinic, but the controlled evidence is weak: several placebo-controlled studies suggest that much of the reported benefit may reflect expectation rather than a direct drug effect. Questions also remain about safety with long-term repeated dosing. Blossom tracks the trials and papers behind microdosing research so you can read the evidence directly, including the studies that found little effect.
Data updated
Key Insights
- 1
This is a theme page about a popular practice, not a condition or a treatment. Microdosing means taking sub-perceptual doses (too small to feel a "trip") of usually LSD or psilocybin, repeatedly, for claimed benefits to mood, focus, creativity and wellbeing.
- 2
The headline finding is that the benefits largely do not survive placebo control. In double-blind trials, including the largest self-blinded study, people taking a microdose improved, but so did people taking a placebo, with no reliable difference between them.
- 3
The gap between anecdote and evidence is the whole story. Surveys and open-label studies are overwhelmingly positive; rigorous controlled trials are mostly null. The most likely explanation is expectancy and self-selection, people who microdose expect and seek benefit, not that the trials are missing a real effect.
- 4
Almost nothing survives a strict test. The clearest exception is a single narrow measure of creative thinking; for ADHD, depression, general cognition and pain, the controlled trials are null. The drugs are biologically active at these doses, but that activity does not translate into reliable benefit.
- 5
Two honest uncertainties remain. A weak or population-specific effect is not ruled out by a handful of small trials, and the long-term safety of taking a serotonergic drug repeatedly for months or years, including a theoretical heart-valve risk, is genuinely unstudied.
By the numbers
- 13
- Trials tracked
- 131
- Papers tracked
- 416
- Trial participants
as of June 2026
as of June 2026
as of June 2026
About Microdosing
Microdosing is not a condition or a treatment; it is a practice, and a hugely popular one. It means taking a dose of a psychedelic so small that it produces no noticeable "trip", typically around a tenth of a recreational dose of LSD or psilocybin, on a repeating schedule such as every third day. People do it hoping for sharper focus, better mood, more creativity, less anxiety, or a general sense of wellbeing, and a large online culture has grown up around protocols, journals and testimonials.
What makes microdosing such an instructive topic is that it is one of the cleanest natural experiments in the whole field for separating real pharmacology from expectation. Because a microdose is, by design, barely perceptible, it is one of the few psychedelic interventions that can actually be blinded properly, you genuinely might not know whether you took it. That makes it testable in a way a full psychedelic dose is not, and the results of those tests are sobering for the practice.
The single most important idea to carry through this page is the gap between how microdosing feels and what it does. The lived experience is often genuinely positive, and that is not in dispute. What is in dispute is whether the drug, rather than the expectation, is responsible, and the best evidence points heavily toward expectation. This page is about holding those two facts together: that many people sincerely feel helped, and that controlled trials struggle to show the drug is doing the helping. The related questions of long-term safety and the underlying pharmacology are covered on their own pages.
Approach & Methods
Because there is no condition here, the relevant "evidence standard" is the quality of the trials, and microdosing is unusually well suited to the gold-standard design. The decisive studies are double-blind and placebo-controlled, and the most elegant is a self-blinding citizen-science study of 191 people who blinded themselves at home[1]: everyone improved, including the placebo group, with no reliable difference between them, leading the authors to conclude the benefits can be explained by the placebo effect. Formal laboratory trials reach the same place. Two double-blind psilocybin trials found no reliable benefit over placebo[2], and another found acute effects only in participants who correctly guessed they had taken the active dose[3].
Against this stands a large, uncontrolled literature that is strongly positive: surveys and naturalistic cohorts, such as one of nearly a thousand psilocybin microdosers showing small-to-medium mood gains[4], and open-label trials with no comparison group. The honest way to read this split is not "some studies say yes, some say no", but "the studies that can tell expectation from drug effect say it is mostly expectation". The most candid counterweight, a rapid review arguing a pure-placebo verdict may be premature given small and possibly under-dosed samples[5], is a fair caution, not a rescue: it concludes only that the question is not fully settled, not that benefit has been shown.
Independent Research
Exploratory Research Report
This report summarises what Blossom’s database shows about microdosing, the practice of taking repeated, sub-perceptual doses of a psychedelic for everyday benefits. It is worth being clear what kind of page this is. It is not a condition page and not a treatment. It is about a hugely popular practice and a striking mismatch: between how reliably people say it helps them and how unreliably it performs when properly tested. That mismatch is the whole subject.
A note before the evidence
This page is a research summary, not medical advice, and nothing here is a recommendation to take psychedelics, including at low doses. It is worth saying plainly that the evidence below is, on the whole, discouraging about microdosing’s specific claims, and that the long-term safety of the practice is genuinely unknown. Read it as an honest accounting, not an endorsement.
Why microdosing is the field’s best natural experiment
Most psychedelic research has a blinding problem: a full dose is unmistakable, so participants know what they took, and expectation contaminates everything. Microdosing is the rare exception. Because a microdose is sub-perceptual by design, people genuinely may not know whether they have taken the drug or a placebo, which makes it one of the few psychedelic interventions that can be blinded properly. That is a gift for science, and the field has used it. The result is an unusually clean body of placebo-controlled evidence, and that evidence is not kind to the practice.
The most elegant study did not even need a lab. In a self-blinding citizen-science project, 191 people randomised their own capsules at home[1]: some got the real microdose, some a placebo, and none knew which. Everyone improved on measures of wellbeing and mood, but the placebo group improved just as much, and the small differences that did appear were explained by people working out which they had taken. The authors’ conclusion was blunt: the anecdotal benefits of microdosing can be explained by the placebo effect.
The controlled trials, one by one, come up null
The formal trials tell the same story across every claim. For attention, the flagship is a phase 2A randomised controlled trial of repeated low-dose LSD for adult ADHD, in which LSD did not beat placebo, and the placebo group improved slightly more[2]. For cognition and mood, two double-blind psilocybin trials found no reliable effect once results were corrected[3], and a careful mushroom study found acute effects only in people who guessed correctly that they had the active dose[4]. For pain, an LSD trial found no analgesia across the sample[5]. For migraine, a psilocybin trial saw roughly equal improvement in every arm, active drug and active placebo alike[6].
The one positive controlled result is worth stating precisely, because it is so narrow. A mega-analysis pooling three blinded trials found that active microdosing raised a single creativity measure, the ratio of original to total responses, with no effect on any other creative or cognitive score[7]. That is the strongest survivor in the entire controlled literature: one sub-measure of divergent thinking. It is a real finding, and it is a long way from "microdosing makes you more creative", let alone "microdosing improves your life".
Why the anecdotes and the trials disagree
The obvious objection is that millions of people swear by microdosing, and the surveys agree with them. A naturalistic study of nearly a thousand psilocybin microdosers found small-to-medium improvements in mood and mental health[8]. So why believe the trials over lived experience? Because the trials are built to answer exactly the question the surveys cannot: is it the drug, or the expectation? Survey and open-label studies cannot separate the two; the people in them know they are microdosing, chose to do it, and expect it to work. When that expectation is held constant by a placebo, the drug’s advantage largely vanishes.
There is a more pointed piece of evidence still. A naturalistic cognition study testing people on and off their microdosing days found no link to better or worse performance in any cognitive domain[9], which suggests that whatever microdosing does, it acts on how people feel rather than on measurable cognition. None of this means people are lying or imagining things. The placebo effect is real and powerful, and feeling better because you expect to is still feeling better. But it is not the same as the drug doing the work, and the distinction matters enormously for anyone deciding whether to take a controlled substance repeatedly on the strength of a pharmacological claim.
The two things the null trials do not settle
Intellectual honesty cuts both ways, and there are two real caveats. The first is that absence of a strong effect is not proof of no effect. The controlled trials are still relatively few, often small, mostly in healthy people, and possibly using doses too low to do anything, a point made fairly by a rapid review that judged a firm placebo verdict premature[10]. A genuine but modest effect, or one confined to a particular population, has not been ruled out, only left unsupported.
The second caveat is the one that should worry enthusiasts most, and it is about safety rather than efficacy. Microdosing is, by definition, a chronic practice, often sustained for months or years, yet almost no one has studied what that does to the body. Short-term, a systematic review found side effects to be mild and short-lived[11]. But these drugs stimulate the 5-HT2B receptor implicated in heart-valve disease, and modelling suggests chronic dosing carries a real if unquantified cardiac risk that no study has been designed to measure[12]. So the practice sits in an uncomfortable place: its headline benefits look largely like placebo, while its main long-term risk is simply unknown.
Reading this honestly
So how should you read the microdosing story? As a humbling one. It is the part of psychedelic science where the experiments are cleanest and the popular claims fare worst. When microdosing is tested the way medicines are tested, double-blind and placebo-controlled, the benefits to mood, focus, cognition and wellbeing very largely fail to separate from placebo, and the small residue tracks expectation rather than chemistry. That does not make the experience fake; the placebo effect is genuine and people really do feel better. But it does mean the specific claim, that a tiny dose of a psychedelic pharmacologically sharpens or lifts you, is not supported by the best evidence, with a single narrow exception in creative thinking. The two honest reservations, that better trials might still find a modest or niche effect, and that the long-term safety of chronic dosing is genuinely unstudied, should temper both the dismissers and the believers. The most useful thing this literature offers an honest reader is a clean demonstration of how powerful expectation is, and a reminder that "it works for me" and "the drug works" are different claims, only one of which the evidence so far supports.
Acute Effect Characterisation
Acute drug effects and evidence levels observed in Microdosing research — characterisation, not therapeutic efficacy.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| LSD This row characterises the microdosing-specific evidence under controlled conditions, not macrodose efficacy. LSD has the best controlled microdosing evidence and it is consistently null or marginal: it did not beat placebo for ADHD (n=53 RCT), pain or mood. Open-label depression signals are uncontrolled. Strong anecdote, weak-to-absent controlled effect. | Small | Moderate | High |
| Psilocybin Microdosing-evidence characterisation, not efficacy. Multiple double-blind placebo-controlled psilocybin trials show no reliable benefit over placebo for cognition, mood or wellbeing; the lone surviving signal is a narrow divergent-thinking measure. Naturalistic benefits are attributed to expectancy. Reliable controlled effect: essentially none. | Small | Moderate | High |
LSD and Microdosing
LSD is one of the two compounds people actually microdose, and it has the most rigorous evidence, which makes its results the most telling. The flagship test is a phase 2A randomised controlled trial of repeated low-dose LSD for adult ADHD, in which LSD was not more efficacious than placebo, and the placebo group actually improved slightly more[1]. A controlled study of LSD microdosing for pain similarly found no analgesic effect across the sample[2], with only a marginal post-hoc hint in a subgroup after the very first dose.
The positive LSD evidence is exactly the kind that cannot settle the question. An open-label trial for depression reported a striking 60% symptom reduction, but it had no placebo group[3], and, tellingly, mood ratings rose on dosing days while the depression measure itself did not move significantly. That pattern, real-feeling improvement that evaporates or fails to reach the formal outcome once a control is introduced, is the signature of this whole literature. LSD is biologically active at these doses, but active is not the same as beneficial.
Psilocybin and Microdosing
Psilocybin is the other widely microdosed compound, and it has been tested in several double-blind, placebo-controlled trials, which is exactly why its story is so deflating for the practice. Two controlled trials found microdosing did not reliably affect cognition, mood or wellbeing once results were corrected for multiple comparisons[1], and a mushroom study found its acute effects appeared only in people who correctly identified that they had the real drug[2], pinning the effect on expectation rather than chemistry.
The one thing that survives is narrow. A mega-analysis pooling three controlled trials found that active microdosing nudged up a single measure, the ratio of original to total responses in a creativity task, with no effect on any other creative or cognitive measure[3]. And a migraine trial found roughly 50% reductions in all arms, including the active placebo, with no significant difference[4]. The fair summary is that psilocybin microdosing, the most-studied version of the practice, has essentially no reliable benefit beyond placebo, with a single thin exception that proves the rule.
Research Outlook
The most useful research direction is, fittingly, the most sceptical: trials designed specifically to separate drug from expectation. Studies that explicitly manipulate expectancy, and that measure whether participants can tell what they took[1] are exactly what this question needs, because the recurring finding is that belief, not pharmacology, drives the apparent effect. The honest counter-case, that existing trials may be too small or under-dosed to detect a real effect[2], is legitimate, and the field would benefit from larger, longer, better-powered trials in specific populations before declaring the matter closed.
The more neglected priority is safety. The short-term picture is reassuring: a systematic review found side effects to be mild, dose-dependent and short-lived[3]. But the practice is, by definition, chronic, and almost no one has studied what taking a serotonergic drug repeatedly for months or years does to the body. The specific concern is the heart: these compounds bind the 5-HT2B receptor implicated in valvular heart disease, and modelling suggests a real if unquantified risk from chronic dosing, with no purpose-designed safety study yet conducted[4]. The outlook, then, is a practice whose benefits look largely illusory under control and whose long-term safety is genuinely unknown, an uncomfortable combination that deserves more rigorous attention than enthusiasm has so far allowed.
Industrial Landscape
Microdosing is unusual in that its momentum comes from the bottom up. The practice was popularised by users, online communities and tech-culture testimonials long before, and largely independently of, formal research, and that grassroots enthusiasm is now a substantial wellness market: protocols, coaching, subscription "stacks" and a steady stream of books and podcasts. Academic researchers, by contrast, have largely played the role of sceptic, running the controlled trials that keep failing to confirm the claims. Commercial drug developers are mostly elsewhere, since a sub-perceptual, hard-to-differentiate product with weak controlled evidence is a difficult thing to build a medicine around.
For an honest broker, microdosing is a case study in how a practice can outrun its evidence, and in how to be fair to both sides. The fair thing to the millions who microdose is to take their experience seriously: many genuinely feel better, and that is real. The fair thing to the evidence is to say plainly that, when tested properly, the drug does not reliably outperform a placebo, and that the felt benefit is very probably expectation, which is powerful and worth respecting but is not what the practice claims. The responsible posture credits the placebo effect honestly rather than dressing it as pharmacology, keeps the door open for a narrow or population-specific effect that better trials might find, and refuses to let the practice off the hook on the one question that should worry everyone: whether it is safe to keep doing for years.
Start here
Top 10 Psychedelic Papers on Microdosing
The 10 most important papers, curated by Blossom
Quick Indicators
Organisations
Search →National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Optimi Health
Canadian GMP-certified manufacturer of pharmaceutical-grade psilocybin and MDMA, licensed by Health Canada. Optimi's facility in Princeton, British Columbia is one of the largest legal psilocybin production operations in North America. Supplies clinical trial material to researchers in Australia, Israel, and Canada.
MycoMedica Life Sciences
MycoMedica Life Sciences PBC is a public benefit corporation developing low-dose psilocybin medicines for psychiatric and neurological disorders. Their lead candidate MLS101 is in Phase 1 clinical development, with PMDD as the lead indication and OUD and OCD as additional targets. Based in Shelton, Washington.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
University of Auckland
The University of Auckland hosts academic psychedelic research activity, including work led by Professor Suresh Muthukumaraswamy on LSD microdosing and related mental health applications.
MindBio Therapeutics
MindBio Therapeutics is a clinical-stage biotechnology company developing MB22001, a proprietary titratable form of LSD designed for take-home microdosing. The company's Phase 2B trials in major depressive disorder and advanced-stage cancer distress have reported strong antidepressant effects, with Phase 2a data showing a 72% reduction in depressive symptoms and 58% remission at six months. MindBio is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange.
Yale University
In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
HHC Research Open Competition
The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.
National Council of Scientific and Technical Research, Argentina
The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.
National University of Natural Medicine
The National University of Natural Medicine (NUNM) is a Portland, Oregon-based accredited institution offering graduate programmes in naturopathic medicine, integrative medicine, and classical Chinese medicine, with a research focus on evidence-based natural health approaches. NUNM co-sponsored the Optimizing Microdosing and Meditation (OMM) trial, studying whether combining psilocybin microdosing with structured mindfulness meditation practice produces synergistic improvements in psychological wellbeing.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Anna Forsyth
Doctoral researcher / researcher at the University of Auckland
She is an author on multiple clinical studies of LSD microdosing in depression and related psychedelic psychiatry work, contributing to early human evidence on efficacy, tolerability, and mechanism.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Laura Alethia de la Fuente
Postdoctoral researcher in neuroscience at CONICET / Instituto de Física de Buenos Aires (IFIBA-UBA)
She co-authored several notable human psychedelic studies on psilocybin microdosing, DMT, and acute psilocybin effects, contributing both behavioral and neurophysiological evidence in the field.
Connected Evidence
The latest clinical data and verified academic findings associated with Microdosing.